Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- IMMX
- Price
- 1.64
- Stock movement up
- +0.07 (4.46%)
- Company name
- Immix Biopharma Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 45.11M
- Ent value
- 33.01M
- Price/Sales
- 9429.86
- Price/Book
- 2.57
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -36.19%
- 3 year return
- -1.95%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-04-18
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
IMMX does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 9429.86 |
| Price to Book | 2.57 |
| EV to Sales | 6900.68 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 27.51M |
| EPS (TTM) | -0.74 |
| FCF per share (TTM) | -0.56 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 4.78K |
| Gross profit (TTM) | -46.44K |
| Operating income (TTM) | -23.09M |
| Net income (TTM) | -21.89M |
| EPS (TTM) | -0.74 |
| EPS (1y forward) | -0.55 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -970.67% |
| Operating margin (TTM) | -214748.36% |
| Profit margin (TTM) | -214748.36% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 19.69M |
| Net receivables | 1.98M |
| Total current assets | 22.76M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 2.39M |
| Total assets | 25.14M |
| Accounts payable | 3.29M |
| Short/Current long term debt | 1.09M |
| Total current liabilities | 6.56M |
| Total liabilities | 7.59M |
| Shareholder's equity | 17.55M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -15.80M |
| Capital expenditures (TTM) | 683.71K |
| Free cash flow (TTM) | -16.48M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -124.73% |
| Return on Assets | -87.07% |
| Return on Invested Capital | -124.28% |
| Cash Return on Invested Capital | -93.57% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.60 |
| Daily high | 1.69 |
| Daily low | 1.60 |
| Daily Volume | 17K |
| All-time high | 7.27 |
| 1y analyst estimate | 7.00 |
| Beta | 0.10 |
| EPS (TTM) | -0.74 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 7 May 2025 |
Downside potential
Loading...
Downside potential data
| IMMX | S&P500 | |
| Current price drop from All-time high | -77.44% | -14.12% |
| Highest price drop | -88.89% | -56.47% |
| Date of highest drop | 10 Nov 2022 | 9 Mar 2009 |
| Avg drop from high | -63.95% | -11.07% |
| Avg time to new high | 167 days | 12 days |
| Max time to new high | 489 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
45.11M
Marketcap category
Small-cap
Description
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
Employees
14
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
No events found
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page